Skip to content
OpenCapital
Get started

Aardvark Therapeutics, Inc. Common Stock AARD Q1 2025 Annual earnings

Reported May 14, 2025 · Before market open

Revenue-Diluted EPS-$0.71Miss by $0.04
EPS estimate-$0.67

Next report

Aug 12, 2026 (in a month)
EPS estimate-$0.86

Financials

Q1 2025

Income statement

See full
Revenue-—
Operating income-$10.5M-382%
Net income-$9.3M-327%
EPS (diluted)-$0.71-29.1%

Balance sheet

See full
Cash & equivalents$26.5M—
Total debt$726.0K—
Total equity$150.7M+508%
Total assets$157.0M—

Cash flow

See full
Operating cash flow-$11.4M-420%
CapEx--100%
Free cash flow-$11.4M-419%

Versus estimates

Diluted EPS

Q1 2026-$0.99Miss by $0.12Q4 2025-$0.81Beat by $0.02Q3 2025-$0.75Beat by $0.05Q2 2025-$0.66Miss by $0.06
Q1 2025-$0.71Miss by $0.04
Q4 2024-$0.68Miss by $0.27

Ask the moment Aardvark Therapeutics, Inc. Common Stock reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Aardvark Therapeutics, Inc. Common Stock report Q1 2025 earnings?
Aardvark Therapeutics, Inc. Common Stock (AARD) reported Q1 2025 earnings on May 14, 2025 before market open.
What were Aardvark Therapeutics, Inc. Common Stock's Q1 2025 revenue and EPS?
Aardvark Therapeutics, Inc. Common Stock reported revenue of - and diluted EPS of $-0.71 for Q1 2025.
Did Aardvark Therapeutics, Inc. Common Stock beat estimates in Q1 2025?
EPS missed the consensus estimate of $-0.67 by $0.04.
Where can I find Aardvark Therapeutics, Inc. Common Stock's Q1 2025 SEC filings?
You can read the 10-K periodic report (0000950170-25-047835) directly on SEC EDGAR. The filing index links above go to sec.gov.